Filippo Pietrantonio, MD, and Federica Morano, MD, on Colorectal Cancer and the MAYA Trial Strategy: Temozolomide, Ipilimumab, and Nivolumab
ESMO Congress 2021
Filippo Pietrantonio, MD, and Federica Morano, MD, both of the Istituto Nazionale dei Tumori, discuss results from the MAYA trial, which provided proof of concept that temozolomide-induced hypermutation may be exploited to achieve durable responses to low-dose ipilimumab plus nivolumab in patients with microsatellite stable metastatic colorectal cancer (Abstract 383O).
The ASCO Post Staff
Robin Cornelissen, MD, PhD, of Erasmus University in Rotterdam, discusses phase II findings from the ZENITH20-4 study, which explored the question of whether poziotinib could benefit patients whose newly diagnosed non–small cell lung cancer harbors EGFR and HER2 exon 20 mutations. Potentially, this novel tyrosine kinase inhibitor may fill an unmet medical need (Abstract LBA46).
The ASCO Post Staff
Gerhardt Attard, MD, PhD, of The Royal Marsden NHS Foundation Trust, discusses findings that show 2 years of abiraterone acetate plus prednisolone-based treatment improves metastasis-free and overall survival in men with high-risk nonmetastatic prostate cancer. The data suggest this combination regimen might be considered a new standard of care (Abstract LBA4).
The ASCO Post Staff
Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, discusses phase III results from the PEACE-1 study, which showed that androgen-deprivation therapy plus docetaxel and abiraterone provided 2.5 years of additional time without radiographic disease progression or death and 1.5 additional years of survival in men with de novo high-volume metastatic castration-sensitive prostate cancer (Abstract LBA5).
The ASCO Post Staff
Nicoletta Colombo, MD, of the Istituto Europeo Oncologico, discusses phase III results that showed improvements in progression-free and overall survival with a combination of pembrolizumab plus chemotherapy, compared with placebo and chemotherapy, for patients with persistent, recurrent, or metastatic cervical cancer. These benefits were seen regardless of PD-L1 expression and concomitant bevacizumab use, suggesting that pembrolizumab plus chemotherapy, with or without bevacizumab, may be a new standard of care for this population (Abstract LBA2).
The ASCO Post Staff
Dieter Hörsch, MD, of Germany’s Central Clinic in Bad Berka, discusses phase III results from the SPINET trial, the largest prospective study to date of the somatostatin analog lanreotide autogel. The study suggests that this agent may prove to be an appropriate treatment option for patients with somatostatin receptor–positive bronchopulmonary neuroendocrine tumors, especially typical carcinoids (Abstract 1096O).
